Metrics as of 10/16/2026, 12:06 AM (Berlin time), refresh in progress.
10x Genomics Stock
10x Genomics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Serge Saxonov
- Employees
- 1,178
- Market cap
- $9.1 B
- IPO
- 12/09/2019
Based in Pleasanton, California, 10x Genomics, Inc. (TXG) is a specialized player in the healthcare/biotechnology sector. Since its founding in 2012, the company has established itself as a manufacturer of instruments, consumables, and software that enable detailed analysis of biological systems. Its offerings include…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
10x Genomics stock: price history
1D
-3.5%
1W
-13.4%
1M
-3.9%
6M
+167.9%
YTD
+328.3%
1Y
+464.3%
2Y
+343.8%
5Y
-54.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~21% stronger price swings than usual
10x Genomics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
2 more assignments (Enabler/Second row) Pro-only.
10x Genomics offers specialized technologies for analyzing biological systems. The company distributes highly complex instruments for single-cell analysis and spatial gene expression, along with associated essential consumables such as microfluidic chips, reagents, and slides. A substantial portion of revenue is generated through recurring sales of consumables, which is based on an installed base of Chromium and Visium platforms. The customer base encompasses a broad range of academic institutions, government organizations, and companies in the biopharmaceutical and biotechnology sectors.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Low
Ask the agents about 10x Genomics
Analyst assessment of 10x Genomics
PRICE TARGET LOW
US$65.00
CONSENSUS
US$83.30
MEDIAN
US$75.00
PRICE TARGET HIGH
US$110.00
0
STRONG BUY
10
BUY
11
HOLD
1
SELL
0
STRONG SELL
22
TOTAL · Hold
As of: 13/10/2026
10x Genomics stock metrics
P/E
-118.41
P/B
11
EV/EBITDA
230.39
RETURN ON EQUITY
-2.2%
NET MARGIN
-11.9%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
89.1%
FLOAT SHARES
116,148,955
AVG. DAILY VOLUME (30D)
3,781,257
Insider transactions (SEC)
Saxonov Serge
SULIMAN SHEHNAAZ
SULIMAN SHEHNAAZ
SULIMAN SHEHNAAZ
SULIMAN SHEHNAAZ
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.5%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about 10x Genomics stock
What does 10x Genomics do?
10x Genomics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Serge Saxonov, the company employs around 1,178 people.
The IPO was on 12/09/2019; the stock trades on NASDAQ under the ticker TXG.
What do analysts say about 10x Genomics stock?
22 analysts rate the stock, the consensus is Hold (as of 13/10/2026).
The average price target is US$83.30, ranging from US$65.00 to US$110.00, with a median of US$75.00.
This is an external assessment, not a statement by Market Jury.
When does 10x Genomics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 21% stronger than usual.
Does 10x Genomics pay a dividend?
No, 10x Genomics currently does not pay a dividend.
Which stocks are comparable to 10x Genomics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get 10x Genomics stock analyzed?
Clicking "Analyze stock" lets five strategies assess 10x Genomics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.